Strategic Alignment Cyprotex benefits from Evotec integration, offering end-to-end ADME-Tox and discovery-to-clinical development support that enables cross-selling with Evotec’s existing client base and expands opportunities for joint projects spanning early discovery to development.

Online Ordering The launch of an e-store for ADME-Tox services creates a streamlined, self-serve procurement channel ideal for fast-moving biotech startups and CROs seeking quick outsourcing, offering a clear path to capture new accounts.

US Presence Despite the 2023 office consolidation in Massachusetts, Cyprotex maintains US facilities and a relocated Framingham site, providing a foothold for targeting US-based pharma and biotech clients through remote delivery and Evotec’s network.

Comprehensive Capabilities A broad ADME-Tox portfolio including high-throughput screening, customized assays, in silico modeling, in vitro toxicology and transcriptomics presents cross-selling opportunities to clients needing integrated, end-to-end toxicology and omics solutions.

Compliance Edge ISO 9001 and ISO/IEC 27001 certifications plus SAP HANA-backed data infrastructure position Cyprotex as a trusted, secure partner for regulated pharma studies, enabling premium outsourcing deals and longer-term contracts.